Personalizing Prostate Cancer Care with the ArteraAI Prostate Test – Jason Hafron, MD
Artificial intelligence is transforming nearly every aspect of healthcare, but what does that actually mean for men with pros [...]
From Testing to Treatment: Implementing Genomics and AI Tools in Prostate Cancer Care – Elisabeth Heath
Elisabeth Heath discusses genomic and AI-based biomarker tools in prostate cancer. Dr. Heath describes ArteraAI as a useful a [...]
External Validation of a Post-RP Multimodal AI Prognostic Model
Prognostication after radical prostatectomy (RP) remains one of the most clinically demanding challenges in prostate cancer m [...]
ArteraAI Offers a New Approach to Breast Cancer Treatment Decision-Making
Matthew Kurian, MD, examines ArteraAI Breast, a newly FDA-cleared multimodal platform that combines pathology imaging and cli [...]
CHHiP Trial Evaluates a Multimodal AI Biomarker in Localized Prostate Cancer – Anna Wilkins
Anna Wilkins describes her validation of the Artera MMAI biomarker, drawing on over 2,000 biopsies from the 3,200-patient CHH [...]
CHHiP Trial Analysis: Prognostic, Risk Stratification Value of MMAI Model for Localized Prostate Cancer
Anna Wilkins, PhD, of Royal Marsden Hospital Institute of Cancer Research (UK), details an external validation of a digital p [...]
Study Investigates an AI-Powered Prognostic Test in Salvage Radiation Therapy Patients – Paul Nguyen
Paul Nguyen discusses the Artera AI prostate test for post-prostatectomy BCR. The test combines clinical factors with AI-anal [...]
Daniel Spratt, MD, on using ArteraAI to guide salvage therapy decisions
On December 9, 2025, Artera announced the commercial launch of the ArteraAI Prostate Test (Post-RP), a tool designed to help [...]
Melvin L.K. Chua, FRCR, PhD, FASCO, on validation of an MMAI model in Asian patients
Data presented at the American Society for Radiation Oncology 67th Annual Meeting validated the performance of the ArteraAI P [...]